Merck

New Phase 2b data for an investigational therapy in adults with #MASH were presented today at #TLM2026 and published in The Lancet. Learn more about the findings and our ongoing research in this chronic, progressive liver disease: go.merck.com/~3a3

Today we announced the initiation of a phase 3 study for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients with a history of them. Learn more about the trial: go.merck.com/~n3w

We’re excited to be at #HIV Glasgow to share new #HIV data. Learn more: go.merck.com/~vnw

Join us today at 9 a.m. ET to learn more about our Q3 2026 #earnings: go.merck.com/~1bo $MRK

Our Q3 2026 #earnings results are live: go.merck.com/~hj7 Swipe below for perspective from Chairman and CEO Rob Davis. $MRK

Today, we presented late-breaking Phase 3 data in certain patients with advanced or recurrent #EndometrialCancer. We remain committed to advancing treatment options that can address unmet needs for those living with this disease. Learn more: go.merck.com/~82i

Today, we announced findings from our Phase 3 trial evaluating our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with endometrial cancer. The results were presented for the first time during a Presidential Symposium at ESMO. go.merck.com/~5wh

We announced positive Phase 3 data for our investigational individualized neoantigen therapy in combination with our company’s immunotherapy for patients with completely resected stage IIB-IV #melanoma in collaboration with @moderna_tx. Read more: go.merck.com/~km1

Today, the European Commission approved a combination regimen for adults with muscle-invasive #BladderCancer (MIBC). Learn more about how we're helping advance cancer care with Pfizer and Astellas: go.merck.com/~oa7

We’re presenting new data from our industry-leading #oncology pipeline and portfolio at this year’s ESMO Congress, including three presentations from pivotal Phase 3 trials in Presidential Symposia. Learn more about our commitment to advancing research across a range of cancer types: go.merck.com/~yuc

Today at #AAO2026, we’re presenting data from our Phase 2b/3 trial of an investigational drug in patients with diabetic macular edema (DME). Learn more: go.merck.com/~4ba

Today we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.merck.com/~73c

Learn more about our latest update in #oncology: go.merck.com/~oolz4s

In collaboration with @EisaiUS, we’re proud to announce today’s #FDA approval of a new combination treatment option for certain patients with advanced renal cell carcinoma, marking an important step forward for people living with #KidneyCancer. Learn more: go.merck.com/~nex

Today, we announced Phase 2b/3 topline results for our investigational therapy in patients with #DiabeticMacularEdema (DME). This important milestone reflects our ongoing commitment to advancing research in #ophthalmology. Learn more: go.merck.com/~k7a

Today, the FDA approved an updated label for a treatment option for adults living with pulmonary arterial hypertension (#PAH). Read more: go.merck.com/~c9i

Learn more about our latest update in #oncology: go.merck.com/~yhzw

Today, we announced a positive CHMP opinion for a combination treatment regimen for adults with resectable muscle-invasive #BladderCancer (MIBC) in the European Union. Read more: go.merck.com/o918

In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma: go.merck.com/~819

We’re pleased to announce the FDA has accepted our filing related to #RSV disease. Learn more: go.merck.com/~dti